Targeting histone acetylation has therapeutic potential in treating diseases characterized by dysregulated gene expression. HDAC inhibitors, for example, are being investigated as treatments for cancer, due to their ability to reactivate tumor suppressor genes. Similarly, modulating HAT activity can have implications in treating neurodegenerative and inflammatory diseases. Thus, understanding the catalytic mechanisms of histone acetylation opens up novel therapeutic avenues.
